



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Andre ROSENTHAL et al.

Confirmation No.: 8558

Serial No.: 09/930,213

Examiner: Marianne P. Allen

Filed: January 31, 2001

Group Art Unit: 1631

Title: DETECTION OF DIFFERENTIAL GENE EXPRESSIONS

RESPONSE TO REQUIREMENT FOR RESTRICTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RECEIVED
AUG 22 2003
TECH CENTER 1600/2960

In response to the Restriction Requirement dated April 16, 2003, Applicants hereby elect, with traverse, Group I (claims 1-15) drawn to a nucleic acid and SEQ ID NO:751 (255 nt Rattus sp. DNA).

Applicants submit that the claims, in particular the claims of Groups I-V, relate to nucleic acids that are differentially expressed in tumor cells relative to normal cells. Thus, a search of these claims would be co-extensive, and would not represent a serious search burden for the patent office. Absent a serious burden of examination, restriction is not proper. See M.P.E.P. §803. Thus, the requirement should be withdrawn.

CERTIFICATE OF MAILING

I hereby certify that this copy of the application was mailed with the
USPS First Class Mail and that the date of mailing was
Certified by the United States Postal Service, Alexandria, VA 22313-
1450.
Name: Andre Rosenthal et al.
Signature: [Handwritten Signature]

ALBRE-14

Declaration

The examiner has deemed the oath or declaration filed April 26, 2002 defective. Applicants are in the process of having a new declaration executed and will forward same to the Office upon receipt.

Drawings

Please delete original figures 11 and 12 without prejudice or disclaimer of the subject matter recited therein.

Specification

Please amend page 17 of the specification as follows:

Figure 11 shows the nucleotide sequences of cDNAs corresponding to the identified differentially expressed transcripts. In addition to the concretely indicated sequences, Fig. 11 also contains, of course, a disclosure relative to the complementary sequences.

Figure 12 shows the nucleotide sequences of homologous human cDNAs. Fig. 12 also contains a disclosure relative to the complementary sequences.

Figure 13 11 shows a correlation of nucleotide sequences (rats) shown in Fig. 11 to the homologous human sequences according to Figure 12 SEQ ID NOS:1-335 and the corresponding T or N clone.


SEQ. ID NOS. 1-885; sequences SEQ. ID NOS. 1, 2, 3 ... 335 correspond to sequences 1, 2, 3 ... 335 according to Fig. 12. Sequences SEQ. ID NOS. 336, 337, 338 ... 632 correspond to sequences nos. 1, 2, 3 ... 297 according to Fig. 11, and sequences SEQ. ID NOS. 633, 634, 635 ... 885 correspond to sequences T1, T2, T3 ... T253 according to Fig. 11.


Sequence Listing

The examiner has stated that the statement under 37 C.F.R. § 1.182(g) is insufficient because it does not state that the paper copy of the sequence listing and the sequence listing on the CRF are identical. A new statement is attached.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,


Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicant(s)


Nicole E. Kinsey, Reg. No. 50,723
Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: August 18, 2003
K:\ALBRE-14.Rsp to RR.doc

